Amgen Inc. will announce its Q3 earnings on November 3, following a strong Q2 where non-GAAP EPS rose 25.8% to $6.29, driven by biosimilars and key drugs like Blincyto and Repatha. Recently, Amgen reported encouraging results from a lung cancer drug study, boosting investor confidence. The company offers a 2.3% yield and trades at a forward EV/EBITDA of 12.9x, presenting an attractive risk/reward profile for investors.
Amgen shares trade at USD 444.76 on Pluang as of Oct 27, 2026 19:12 WIB, near their 52-week high of USD 447.28. The stock shows a modest 1-day gain of 0.03% and offers a dividend yield of 2.27%. This steady performance complements the upcoming Q3 earnings announcement noted in the news.
Amgen has appointed David W. Gibbs, former CEO of Yum! Brands, to its Board of Directors. Gibbs brings extensive leadership experience from the consumer brand sector and will serve on Amgen's Audit and Compensation Committees. His background in digit...
A late-stage trial found that adding Amgen's Imdelltra to AstraZeneca's Imfinzi immunotherapy reduced the risk of death by 58% in patients with extensive-stage small cell lung cancer, extending median survival to 21.1 months from 12.7 months with Imf...
Amgen announced Phase 3 DeLLphi-305 trial results where IMDELLTRA combined with AstraZeneca's IMFINZI reduced death risk by 58% and extended median overall survival to 21.1 months in extensive-stage small cell lung cancer patients. Nearly 80% of pati...
